Lantern Pharma Reports Q1 2025 Financial Results

Lantern Pharma ( (LTRN) ) has issued an announcement.

Lantern Pharma announced its first quarter 2025 financial results and business updates, highlighting key advancements in its AI-driven drug development pipeline. The company completed enrollment for its LP-184 Phase 1a clinical trial and anticipates additional data readouts for its LP-300 HARMONIC™ Trial in Q3 2025. Lantern has expanded its RADR® platform with new AI-powered modules to enhance antibody-drug conjugate development and is planning the commercial launch of select AI modules for the scientific community. The company also reported maintaining disciplined capital management with $19.7 million in cash and equivalents, providing an operating runway through May 2026.

The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.

Spark’s Take on LTRN Stock

According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.

Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.

To see Spark’s full report on LTRN stock, click here.

More about Lantern Pharma

Lantern Pharma Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development.

Average Trading Volume: 40,003

Technical Sentiment Signal: Hold

Current Market Cap: $44.33M

For an in-depth examination of LTRN stock, go to TipRanks’ Stock Analysis page.